Looks like there are four companies doing pd1 / pdl1 trials. Any insight into whether one pd1 / pdl1 trial is better than another? It appears Merck is starting one at UCSF now and Roche at Stanford sometime in the future. Is there something we should be looking for? Would be used as first line instead of traditional three drug chemo treatment.
NSCLC, Adenocarcinoma 2A Feb 2012, Male Non Smoker 47, surgery and chemo. Reoccurrence in lung July 2013. Brain and bone scan clean.